Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cartesian Therapeutics (RNAC) EBITDA: 2014-2024

Historic EBITDA for Cartesian Therapeutics (RNAC) over the last 11 years, with Dec 2024 value amounting to -$77.4 million.

  • Cartesian Therapeutics' EBITDA fell 48.41% to -$35.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$48.0 million, marking a year-over-year increase of 80.41%. This contributed to the annual value of -$77.4 million for FY2024, which is 64.76% up from last year.
  • Cartesian Therapeutics' EBITDA amounted to -$77.4 million in FY2024, which was up 64.76% from -$219.8 million recorded in FY2023.
  • Cartesian Therapeutics' EBITDA's 5-year high stood at $35.4 million during FY2022, with a 5-year trough of -$219.8 million in FY2023.
  • Its 3-year average for EBITDA is -$87.3 million, with a median of -$77.4 million in 2024.
  • Per our database at Business Quant, Cartesian Therapeutics' EBITDA soared by 237.75% in 2022 and then crashed by 721.00% in 2023.
  • Over the past 5 years, Cartesian Therapeutics' EBITDA (Yearly) stood at -$68.9 million in 2020, then spiked by 62.72% to -$25.7 million in 2021, then skyrocketed by 237.75% to $35.4 million in 2022, then tumbled by 721.00% to -$219.8 million in 2023, then spiked by 64.76% to -$77.4 million in 2024.